secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000950170-22-020699
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q3 net loss $27.7M, expands Pfizer ADC licensing deal
--------------------------------------------------------------------

- Net loss of $27.7M ($0.85 per share) for Q3 2022 vs. $14.2M ($8.96 per share) in Q3 2021.
- Cash and cash equivalents (incl. restricted) $200.0M as of Sept 30, 2022; expected to fund operations into end of 2024.
- Expanded worldwide licensing deal with Pfizer for exclusive rights to Pfizer’s ADC technology platform and toolkit.
- First multi-target sublicensing agreement executed with a stealth ADC company under the new Pfizer arrangement.
- IND filings for PYX-106 and PYX-201 on track by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/0000950170-22-020699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/pyxs-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer